Phase 1a/1b dose-escalating trial of VE303 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2018
At a glance
- Drugs VE 303 (Primary) ; Vancomycin
- Indications Clostridium difficile infections
- Focus Adverse reactions; First in man
- 12 Dec 2018 Status changed from recruiting to completed, according to a PureTech Health media release.
- 04 Oct 2018 According to a Vedanta Biosciences media release, additional exploration of VE303 in healthy volunteers to inform dose selection in other indications is ongoing.
- 04 Oct 2018 Interim results presented in the Vedanta Biosciences media release.